Holen Sie sich die Stockscreener-App
7.295
5.19%
-0.415
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$7.71
Offen:
$7.79
24-Stunden-Volumen:
529.47K
Relative Volume:
0.43
Marktkapitalisierung:
$566.41M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-102.44M
KGV:
-2.3997
EPS:
-3.04
Netto-Cashflow:
$-91.73M
1W Leistung:
+8.30%
1M Leistung:
+18.09%
6M Leistung:
+35.62%
1J Leistung:
+42.08%
1-Tages-Spanne:
$7.27
$7.84
1-Wochen-Bereich:
$6.60
$8.72
52-Wochen-Spanne:
$2.41
$8.72
Solid Biosciences Inc Stock (SLDB) Company Profile
Firmenname
Solid Biosciences Inc
Sektor
Branche
Telefon
617-337-4680
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
7.27 | 600.69M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.30 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.20 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.47 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.53 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.27 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Eingeleitet | Needham | Buy |
| 2025-06-26 | Eingeleitet | Citigroup | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-13 | Eingeleitet | Wedbush | Outperform |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-15 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | William Blair | Outperform |
| 2024-03-15 | Eingeleitet | Citigroup | Buy |
| 2024-03-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-05-27 | Eingeleitet | Jefferies | Buy |
| 2021-03-16 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-29 | Herabstufung | Citigroup | Neutral → Sell |
| 2019-08-19 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Herabstufung | Goldman | Neutral → Sell |
| 2019-02-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-02-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Eingeleitet | Citigroup | Sell |
| 2018-09-06 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Solid Biosciences reports interim data from Duchenne gene therapy trial - Investing.com Australia
Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start (NASDAQ:SLDB) - Seeking Alpha
Solid Biosciences says interim results reinforce confidence in SGT-003 potential - Yahoo Finance
SLDB: Wedbush Raises Price Target, Maintains Outperform Rating | - GuruFocus
Truist reiterates Buy on Solid Biosciences stock after trial data - Investing.com
Solid Biosciences (SLDB): Chardan Capital Maintains Buy Rating w - GuruFocus
Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data - TipRanks
Solid Bio’s SGT-003 Data Show DMD Gene Therapy Efficacy Without Liver Toxicity - Citeline News & Insights
Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned - Benzinga
Solid Biosciences (SLDB) Shares Drop After New Trial Data Releas - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Shares Down 6.3%Time to Sell? - MarketBeat
Solid Biosciences shares fall after gene therapy trial data - Investing.com
Solid Bio falls amid new data for Duchenne drug (SLDB:NASDAQ) - Seeking Alpha
Solid Biosciences shares fall after gene therapy trial data By Investing.com - Investing.com Canada
Solid Biosciences (SLDB) Reveals Encouraging Interim Data from S - GuruFocus
Solid Biosciences Inc. unveils positive interim data from Duchenne gene therapy trial - Traders Union
Solid Biosciences Provides Interim Positive Clinical Update On Phase 1/2 Inspire Duchenne Trial - TradingView
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial - GlobeNewswire
Wedbush Reiterates Outperform Rating for SLDB with $14 Price Tar - GuruFocus
Wedbush Reaffirms "Outperform" Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Big Money Moves: Will Solid Biosciences Inc stock recover after earnings2026 Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Solid Biosciences Secures $240 Million in Private Placement - Global Legal Chronicle
Solid Biosciences (NASDAQ:SLDB) Reaches New 1-Year HighShould You Buy? - MarketBeat
Solid Biosciences secures $240M private placement funding By Investing.com - Investing.com Canada
Solid Biosciences Announces $240 Million Private Placement Financing - TipRanks
Solid Biosciences Raises $240 Million in Private Placement of Stock and Pre-Funded Warrants - TradingView
Solid Biosciences Inc. announced that it expects to receive $239.972139 million in funding - marketscreener.com
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - Bitget
Solid Biosciences (SLDB) Announces $240M Private Placement - GuruFocus
Solid Biosciences Announces Oversubscribed $240 Million Private Placement - Bitget
Solid Biosciences announces $240 million private placement - MSN
Solid Biosciences secures $240M private placement funding - Investing.com India
Solid Biosciences Commences $240 Million Private Placement of Common Shares, Pre-Funded Warrants - marketscreener.com
Solid Biosciences stock jumps on $240M private placement - Investing.com
Solid Biosciences stock jumps on $240M private placement By Investing.com - Investing.com Nigeria
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
SLDB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Solid Biosciences (SLDB) Stock Price, News & Analysis - MarketBeat
Biotech Sector Sustains After-Hours Trading Gains - Intellectia AI
Solid Biosciences (SLDB) Projected to Post Earnings on Thursday - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Solid Biosciences Inc. sponsors international muscular dystrophy conference in Rome - Traders Union
SLDB SEC FilingsSolid Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Solid Biosciences CTO Herzich sells $21k in shares By Investing.com - Investing.com South Africa
Solid Biosciences CEO Cumbo sells $96k in shares By Investing.com - Investing.com Canada
Solid Biosciences CTO Herzich sells $21k in shares - Investing.com India
Solid Biosciences COO Howton sells $43k in shares - Investing.com Australia
Patterns Watch: What are Solid Biosciences Incs earnings expectationsMarket Activity Recap & Safe Entry Trade Signal Reports - baoquankhu1.vn
David Howton Sells 7,469 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat
Insider Selling: Solid Biosciences (NASDAQ:SLDB) CEO Sells $96,868.08 in Stock - MarketBeat
Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):